Gufic Biosciences Limited has submitted to the Exchange, the Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended September 30, 2025.
GUFICBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.8 pts less than Nifty Microcap 250 and 2.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Gufic Biosciences has submitted its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 to the stock exchanges. This is a routine regulatory filing required under SEBI listing norms, typically filed within 45 days of quarter-end. The actual financial numbers, including revenue, profit, and margin details, would be detailed in the submitted results document and accompanying investor presentation. As of this filing, no specific figures, auditor qualifications, or material concerns have been highlighted in the announcement itself.
This is a procedural compliance filing and does not directly impact share price. Investors should review the detailed results document for actual revenue, profit, and margin trends to gauge the company's operational performance for the quarter.